Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07196046 · ClinicalTrials.gov registry record · NA

Product Responsiveness to Enhanced Bioavailability Curcumin Dietary Supplements in Adults

A NA study of Quality of Life (QOL) and Joint Discomfort, sponsored by Ultra Botanica.

Active
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT07196046: Active NA study of Quality of Life (QOL) and Joint Discomfort, sponsored by Ultra Botanica.

NCT07196046 is a NA study of Quality of Life (QOL) and Joint Discomfort that is active but no longer recruiting, run by Ultra Botanica. The registered enrollment target is 30 participants, below the 143-participant average among 3 other Quality of Life (QOL) trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07196046, a NA study of Quality of Life (QOL) and Joint Discomfort, is active but no longer recruiting, sponsored by Ultra Botanica.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to evaluate whether distinct formulations of bioavailable curcumin supplements can improve joint comfort in adults who experience self-reported discomfort. Participants will also receive a placebo during the study, but they will not know when they receive it. The main questions it aims to answer are: * Do participants report improved joint comfort after taking each curcumin-based supplement? * Are there difference in quality-of-life scores or pain perceptions between the products? Researchers will compare the effects of the different formulations of bioavailable curcumin supplements to see if one provides greater improvements in joint comfort and related outcomes. Participants will: * Wear a fitness tracker starting at the time of electronic consent to provide continuous data on physical activity, heart rate, and sleep * Complete multiple blinded study periods involving different oral supplements, each separated by a washout period * Take one supplement twice daily during each intervention period, with intervention periods lasting between approximately two and four weeks * Complete washout periods of approximately one week between intervention periods * Complete the validated RAND-36 quality-of-life questionnaire and other study-specific questionnaires adapted from commonly used pain and global impression scales to assess joint comfort, pain perception, and overall health * Participate in a 30-day follow up period after the final supplement to complete final questionnaires and wearable data collection The study is conducted remotely using the Alethios decentralized research platform.

Primary Outcome

Change in RAND-36 scores across the eight domains (physical functioning, role limitations, pain, general health, vitality, social functioning, emotional well-being, and mental health). Scores will be compared within and across supplement phases to evaluate participant-perceived quality of life.

Interventions

  • DIETARY_SUPPLEMENT Supplement 2
  • DIETARY_SUPPLEMENT Supplement 3
  • DIETARY_SUPPLEMENT Supplement 1

Study Locations (1)

Oklahoma

  • Ultra Botanica LLC - Oklahoma City

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-12-10
Est. Completion 2026-08
Phase NA
Ultra Botanica

1 total trials

What the registry record for NCT07196046 still lists

NCT07196046 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 143-participant average among 3 other Quality of Life (QOL) trials with a reported enrollment target (79% lower).

The record links to 2 conditions, with Quality of Life (QOL) appearing as the primary indexed condition, and to 3 interventions - of which Supplement 2 is the first listed.

NCT07196046 reports a single indexed study location in Oklahoma.

Frequently Asked Questions

What is clinical trial NCT07196046 about?

NCT07196046 is a clinical study titled "Product Responsiveness to Enhanced Bioavailability Curcumin Dietary Supplements in Adults". The goal of this clinical trial is to evaluate whether distinct formulations of bioavailable curcumin supplements can improve joint comfort in adults who experience self-reported discomfort. Participants will also receive a placebo during the study, but they will not know when they receive it. The ...

What is the current status of trial NCT07196046?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-12-10. Estimated completion is 2026-08.

What conditions does trial NCT07196046 study?

This clinical trial studies the following conditions: Quality of Life (QOL), Joint Discomfort.

What interventions are being tested in trial NCT07196046?

The interventions under investigation include: Supplement 2 (DIETARY_SUPPLEMENT), Supplement 3 (DIETARY_SUPPLEMENT), Supplement 1 (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07196046?

This trial is sponsored by Ultra Botanica, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07196046 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Quality of Life (QOL)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07196046, the US trial registry maintained by the National Library of Medicine. NCT07196046 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.